[Identification, evaluation and treatment of dementia patients in society].
Patients with "mild to moderate" dementia might improve with appropriate drug therapy whereas patients with "severe" dementia are generally considered to have an irreversible condition, providing acute metabolic disorders have been excluded and appropriate investigations have been performed to exclude neurological conditions that might be amenable to neurosurgery. Since it is unlikely that this type of patient will be referred to the hospital outpatient clinics, it is necessary to identify these patients in the community. For this purpose, authors have used the Abbreviated Mental Test. A comparison between two observers (nurse and doctor) has been made. Subsequently, a 6 symptoms check-list, as abbreviated form of the Crichton Royal Rating Scale for geriatric patients, was used in an open pilot study on 260 patients completing a 12 weeks treatment by dihydroergotoxine mesylate (codergocrine mesylate, Hydergine) 4.5 mg once a day. Although this was an open pilot study, it does show that it is possible to identify and treat patients with "mild to moderate" dementia in the community. A single dose formulation in the elderly has obvious advantages. In this study, compliance was excellent and 88% of the patients showed significant improvement using the suggested rating scales.
D000553:Ambulatory Care; D000704:Analysis of Variance; D003704:Dementia / Q000175:diagnosis / Q000628:therapy*; D004088:Dihydroergotoxine / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D006801:Humans; D007361:Intelligence Tests; D011379:Prognosis; D011567:Psychiatric Department, Hospital
D004088:Dihydroergotoxine
Identification, évaluation et traitement des malades déments dans la société.